Anlon Healthcare Limited is a chemical manufacturing company engaged in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs).
The company specializes in high-purity intermediates used for API production and APIs that are integral to formulations in medicines, nutraceuticals, personal care, and animal health products. All products are manufactured in compliance with Indian and international pharmacopeia standards including IP, BP, EP, JP, and USP.
In addition to its core manufacturing business, Anlon has expanded into custom manufacturing of complex chemicals, delivering solutions with enhanced purity and reduced impurities tailored to customer requirements.
The company has received Drug Master File (DMF) approvals from ANVISA (Brazil), NMPA (China), and PMDA (Japan) for loxoprofen sodium dihydrate and loxoprofen acid APIs. Till date, it has filed 21 DMFs with global authorities and is in the process of seeking approvals for Ketoprofen and Dexketoprofen Trometamol.
Anlon’s product portfolio is diversified, comprising:
- 65 commercialized products
- 28 products at the pilot stage
- 49 products in laboratory testing
The company ensures product quality through rigorous testing, analysis, and continuous process improvements. Its operations are supported by four dedicated laboratories and a 34-member scientific team, including 24 science graduates, ensuring strict adherence to customer and industry standards.
Products:
- Pharma Intermediates – Examples include Cyanoethylbenzoic Acid, Ketonitrile, and Methyldesloratadine, which serve as key starting materials or advanced intermediates in API manufacturing.
- Active Pharmaceutical Ingredients (APIs) – Used in formulations such as tablets, capsules, ointments, syrups, as well as in nutraceuticals, personal care, and veterinary products.
As of January 31, 2025, Anlon Healthcare employed 105 people (excluding trainees) along with 8 contract workers.
Anlon Healthcare IPO – Details
| IPO Opening Date | 26 August 2025 |
| IPO Closing Date | 29 August 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | Total Issue Size: 1,33,00,000 Shares Worth ₹121.03 Crore Fresh Issue: 1,33,00,000 Shares Worth ₹121.03 Crore |
| Face Value | ₹10 per equity share |
| IPO Price | ₹86 – ₹91 per share |
| Market Lot | 164 Shares |
| Min Order | 164 Shares [ 1 Lot ] |
| Listing At | BSE, NSE |
| Register | Kfin Technologies Ltd. |
| QIB Shares Offered | 75% |
| NII (HNI) Shares Offered | 15% |
| Retail Shares Offered | 10% |
Anlon Healthcare IPO – Date Schedule
| IPO Open Date | 26 August 2025 |
| IPO Close Date | 29 August 2025 |
| Basis of Allotment | 01 September 2025 |
| Initiation of Refund | 02 September 2025 |
| Credit of Shares to Demat Account | 02 September 2025 |
| IPO Listing Date | 03 September 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 29, 2025 |
Anlon Healthcare IPO – Lots Size & Price
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
Competitive Strength
- Strong product portfolio and scalable business.
- Strong Promoters and Experienced Management Team.
- High entry and exit barriers due to long customer approval cycles and strict product standards.
- In-house Testing, Quality Control and Quality Assurance for quality control.
- Focus on Quality, Environment, Health and Safety.
Company Promoters
- Punitkumar R. rasadia
- Meet Atulkumar Vachhani
- Mamata punitkumar Rasadia
Company Financials
| Particulars | Total Revenue | Total Expense | Profit After Tax | Total Borrowing |
|---|---|---|---|---|
| 31 March 2022 | ₹57.54 Cr | ₹57.64 Cr | – ₹0.11 Cr | ₹60.32 Cr |
| 31 March 2023 | ₹113.12 Cr | ₹106.13 Cr | ₹5.82 Cr | ₹66.39 Cr |
| 31 March 2024 | ₹66.69 Cr | ₹56.94 Cr | ₹9.66 Cr | ₹74.56 Cr |
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 21.93% |
| ROCE | 0.73 |
| Debt/Equity | 25.21% |
| RoNW | 17.06% |
| PAT Margin | 26.88% |
| Price to Book Value | 4.51 |
| Pre IPO | Post IPO | |
| EPS (₹) | 6.38 | – |
| P/E (x) | 14.26 | – |
Object Of The Issue
| Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|
| Funding capital expenditure requirements for Proposed Expansion. | ₹30.72 |
| Full or part repayment and/or prepayment of certain outstanding secured borrowing (term loan)availed by the Company. | ₹50.00 |
| Funding the working capital requirements of the Company. | ₹43.15 |
| General corporate purposes. |
Anlon Healthcare IPO Peer Comparison
| S. No. | Face Value (₹) | Company Name | P/E Ratio |
|---|---|---|---|
| 1 | 10 | Kronox Lab Sciences Limited | 26.72 |
| 2 | 10 | AMI Organics Limited | 197.70 |
| 3 | 2 | Supriya Lifesciences Limited | 49.52 |
✅Strengths
- Diversified product portfolio of APIs, pharma intermediates, and specialty chemicals.
- Strong R&D focus with four labs and experienced scientific team.
- Global regulatory presence with 21 DMFs filed and approvals from ANVISA, NMPA, and PMDA.
- Established relationships with domestic and international customers.
- Growing capabilities in custom synthesis and contract manufacturing.
⚠️Risks
- Significant dependence on a limited number of products and customers.
- Exposure to stringent regulatory norms; non-compliance can impact business.
- Intense competition from domestic and international API manufacturers.
- Dependence on import of raw materials; price fluctuations may affect margins.
- Subject to foreign exchange fluctuations due to global operations.
Anlon Healthcare IPO Promoter Holding
| Pre Issue Share Holding | 70.26% |
| Post Issue Share Holding | 52.68% |
Anlon Healthcare IPO Prospectus
- Anlon Healthcare IPO DRHP
- Anlon Healthcare IPO RHP
Company Contact Information
| Anlon Healthcare Ltd. 101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005 Phone: +91 281 2562538 Email: cs@anloncro.com Website: http://www.anlon.in/ |
Anlon Healthcare IPO Registrar
| Kfin Technologies Ltd. Phone: 04067162222, 04079611000 Email: ahl.ipo@kfintech.com Website: https://ipostatus.kfintech.com/ |
Anlon Healthcare IPO Lead Manager(s)
| 1. Interactive Financial Services Ltd. |
Anlon Healthcare IPO FAQs
| What is Anlon Healthcare IPO? Anlon Healthcare IPO is a main-board IPO. The issue is priced at ₹86 to ₹91 per equity share. The IPO is to be listed on BSE & NSE. |
| When will Anlon Healthcare IPO open? The IPO is to open on 26 August 2025 for QIB, NII, and Retail Investors. |
| What is Anlon Healthcare IPO Investors Portion? The investors’ portion for QIB – 75%, NII – 15%, and Retail – 10%. |
| What is Anlon Healthcare IPO Size? Anlon Healthcare IPO size is ₹121.03 Crore. |
| What is the Anlon Healthcare IPO Minimum and Maximum Lot Size for Retail? The minimum bid is 164 Shares with ₹14,924 while the maximum bid is 2132 Shares with ₹1,94,012. |
| What is the Anlon Healthcare IPO Allotment Date? Anlon Healthcare IPO allotment date is 01 September 2025. |
| What is the Anlon Healthcare IPO Listing Date? Anlon Healthcare IPO listing date is 03 September 2025. The IPO is to be listed on BSE and NSE. |
